Results 111 to 120 of about 6,404 (193)

Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine

The varicella-zoster virus (VZV) is a human neurotropic herpes virus responsible for varicella and herpes zoster (HZ). Following primary infection in childhood, VZV manifests as varicella (chickenpox) and enters a period of latency within the dorsal root
Ryuhei Ishihara, Masao Katsushima, Kazuo Fukumoto, Ryu Watanabe, Mayu Shiomi, Tadashi Okano, Motomu Hashimoto, Shinsuke Yamada   +7 more
core   +1 more source

Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in US Medicare Adults Age 65 Years or Older. [PDF]

Drug Saf
Dos Reis S, Chiang YY, Amill-Rosario A, Lee H, Johnson A, Ryan K, Oraichi D, Seifert H, Yun H, Gamble S, Spence O.   +10 more
europepmc   +1 more source

Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression. [PDF]

RMD Open
Krasselt M.
europepmc   +1 more source

Repeated dose toxicity and immunogenicity studies in SD rats: a new recombinant zoster vaccine (CHO cell) formulated with adjuvant BC02. [PDF]

Front Cell Infect Microbiol
Yang Q, Yang L, Zhao A, Ge L, Liu F, Yang Z, Huang Y, Jiang Q, Deng Y, Hu X, Wang J, Xia L, Zhang S, Liang F, Lu W, Zhu K, Xu P, Tan X, Huang W.   +18 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Recombinant Zoster Vaccine at Age 50 for Chinese Adults with Mild Cognitive Impairment: A Modelling Study. [PDF]

Vaccines (Basel)
Wu Y, Yao Y, Liu J.
europepmc   +1 more source

Safety profile of the adjuvanted recombinant zoster vaccine

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.
López Fauqued, Marta||, Campora, Laura, Delannois, Frédérique, El Idrissi, Mohamed||, Oostvogels, Lidia||, De Looze, Ferdinandus||, Diez-Domingo, Javier||, Heineman, Thomas||, Lal, Himal, McElhaney, Janet||, McNeil, Shelly||, Yeo, Wilfred||, Tavares-Da-Silva, Fernanda||, Ahonen, Anitta, Avelino-Silva, Thiago||, Barba-Gomez, José Fernando, Berglund, Johan||, Brotons, Carlos||, Caso, Covadonga, Chlibek, Roman, Choi, Won Suk||, Cunningham, Anthony||, Desole, Maria Giuseppina, Eizenberg, Peter, Esen, Meral, Espié, Emmanuelle, Gervais, Pierre, Ghesquiere, Wayne, Godeaux, Olivier O., Gorfinkel, Iris, Hui, David Shu Cheong, Hwang, Shinnjang, Korhonen, Tiina, Kovac, Martina||, Ledent, Edouard Y., Leung, Edward Man Fuk, Levin, Myron||, Perez, Silvia Narejos, de Andrade Neto, José Luiz, Pauksens, Karlis, Poder, Airi, Rodriguez de la Pinta, Maria Luisa||, Rombo, Lars, Schwarz, Tino Francis, Smetana, Jan||, Staniscia, Tommaso||, Tinoco-Fávila, Juan Carlos, Toma, Azhar, Vastiau, Ilse, Vesikari, Timo H., Volpi, Antonio, Watanabe, Daisuke||, Weckx, Lily||, Zahaf, Toufik||   +53 more
openaire   +1 more source

Impaired humoral and cellular immune responses to recombinant zoster vaccine in kidney transplant recipients treated with belatacept. [PDF]

Clin Kidney J
de Nattes T, Van Wynsberghe M, Lemée V, Hanoy M, Candon S, Bertrand D.   +5 more
europepmc   +1 more source

Widening access to recombinant zoster vaccination in IBD

The Lancet Gastroenterology & Hepatology
Alexander, James L, Powell, Nick, Caldera, Freddy, Kennedy, Nick, Din, Shahida   +4 more
openaire   +2 more sources

Effectiveness and safety of the recombinant zoster vaccine in adults aged ≥50 years with inflammatory bowel disease. [PDF]

Hum Vaccin Immunother
Tseng HF, Sy LS, Rayens E, Ackerson BK, Ku JH, Wu J, Luo Y, Cheng Y, Patel AR, Solano Z, De Jesus J, Amundsen B, Florea A, Chmielewski-Yee E, Oraichi D, Seifert H, Yun H, Qian L.   +17 more
europepmc   +1 more source

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) \u2014 United States, October 2017\u2013June 2018: Supplementary Table 2. Prespecified Outcomes , for Recombinant Zoster Vaccine (RZV) in Reports Submitted to the Vaccine Adverse Events Reporting System (VAERS) \u2014 United States, October 2017\u2013June 2018

Supplementary Table for: Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) \u2014 United States, October 2017\u2013June ...

core